U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Qayyum R, Wilson LM, Bolen S, et al. Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Sep. (Comparative Effectiveness Reviews, No. 14.)

  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes

Comparative Effectiveness, Safety, and Indications of Insulin Analogues in Premixed Formulations for Adults With Type 2 Diabetes [Internet].

Show details

Appendix ADetailed Electronic Database Search Strategies

MEDLINE Strategy

TermsReturns
((“diabetes mellitus, type 2”[mh] OR “type 2 diabetes”[tiab] OR ((diabetes[tiab] OR diabetics[tiab] OR diabetic[tiab]) AND (“non-insulin dependent”[tiab] OR “type 2”[tiab] or type-2[tiab] OR “type II”[tiab]))) AND (“insulin/analogs and derivatives”[mh] OR “BIAsp 30”[tiab] OR “BIAsp30”[tiab] OR (Humalog[tiab] AND (Mix[tiab] OR 25[tiab] OR 50[tiab])) OR (NovoLog[tiab] AND (Mix[tiab] OR 70[tiab] OR 30[tiab])) OR (insulin[tiab] AND ((biphasic[tiab] OR premixed[tiab] OR “pre-mixed”[tiab] OR protamin*[tiab] OR Mix[tiab] OR mixture[tiab]) OR (aspart[tiab] OR lispro[tiab] OR analogue[tiab] OR analogues[tiab] OR analog[tiab] OR analogs[tiab] OR Humalog[tiab]))))) NOT (animals[mh]NOT humans[mh])1149

EMBASE Strategy

((‘non insulin dependent diabetes mellitus’/exp OR ‘type 2 diabetes’:ti,ab OR ((diabetes:ti,ab OR diabetics:ti,ab OR diabetic:ti,ab) AND (‘non-insulin dependent’:ti,ab OR ‘type 2’:ti,ab or type-2:ti,ab OR ‘type II’:ti,ab))) AND (‘biphasic insulin’/exp OR ‘BIAsp 30’:ti,ab OR ‘BIAsp30’:ti,ab OR (Humalog:ti,ab AND (Mix:ti,ab OR 25:ti,ab OR 50:ti,ab)) OR (NovoLog:ti,ab AND (Mix:ti,ab OR 70:ti,ab OR 30:ti,ab)) OR ((insulin:ti,ab AND (biphasic:ti,ab OR premixed:ti,ab OR ‘pre-mixed’:ti,ab OR protamin*:ti,ab OR Mix:ti,ab) OR (aspart:ti,ab OR lispro:ti,ab OR analogue:ti,ab OR analogues:ti,ab OR analog:ti,ab OR analogs:ti,ab OR Humalog:ti,ab))))) NOT ([animals]/lim NOT [humans]/lim)1344

Cumulative Index to Nursing and Applied Health Literature (CINAHL)

(((MH “Diabetes Mellitus, Non-Insulin-Dependent”) OR (TX “type 2 diabetes”) OR (((TX “diabetes”) OR (TX “diabetics”) OR (TX “diabetic”)) AND ((TX “non-insulin dependent”) OR (TX “type 2”) or (TX “type-2”) OR ( TX “type II”)))) AND ((MH “Insulin/AA”) OR (TX “BIAsp 30”) OR (TX “BIAsp30”) OR ((TX “Humalog”) AND ((TX “Mix”) OR (TX “25”) OR (TX “50”))) OR ((TX “NovoLog”) AND ((TX “Mix”) OR (TX “70”) OR (TX “30”))) OR ((TX “insulin”) AND (((TX “biphasic”) OR (TX “premixed”) OR (TX “pre-mixed”) OR (TX “protamin*”) OR (TX “Mix”) OR (TX “mixture”)) OR ((TX “aspart”) OR (TX “lispro”) OR (TX “analogue”) OR (TX “analogues”) OR (TX “analog”) OR (TX “analogs”) OR (TX “Humalog”))))))299

The Cochrane Central Register of Controlled Trials (CENTRAL)

#1 (type 2 diabetes):ti,ab,kw in Clinical Trials

#2 (diabetes):ti,ab,kw or (diabetics):ti,ab,kw or (diabetic):ti,ab,kw in Clinical Trials

#3 (non-insulin dependent):ti,ab,kw or (type 2):ti,ab,kw or (type-2):ti,ab,kw or (type II):ti,ab,kw in Clinical Trials

#4 (#2 AND #3)

#5 (#1 OR #4)

#6 (BIAsp 30):ti,ab,kw or (BIAsp30):ti,ab,kw in Clinical Trials

#7 (Humalog):ti,ab,kw in Clinical Trials

#8 (Mix):ti,ab,kw or (25):ti,ab,kw or (50):ti,ab,kw in Clinical Trials

#9 (#7 AND #8)

#10 (NovoLog):ti,ab,kw in Clinical Trials

#11 (Mix):ti,ab,kw or (70):ti,ab,kw or (30):ti,ab,kw in Clinical Trials

#12 (#10 AND #11)

#13 (insulin):ti,ab,kw in Clinical Trials

#14 (biphasic):ti,ab,kw or (premixed):ti,ab,kw or (pre-mixed):ti,ab,kw or (protamin*):ti,ab,kw or (mix):ti,ab,kw in Clinical Trials

#15 (mixture):ti,ab,kw in Clinical Trials

#16 (#14 OR #15)

#17 (aspart):ti,ab,kw or (lispro):ti,ab,kw or (analogue):ti,ab,kw or (analogues):ti,ab,kw or (analog):ti,ab,kw in Clinical Trials

#18 (analogs):ti,ab,kw or (Humalog):ti,ab,kw in Clinical Trials

#19 (#17 OR #18)

#20 (#16 OR #19)

#21 (#13 AND #20)

#22 (#6 OR #9 OR #12 OR #21)

#23 (#5 AND #22)
654

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (3.9M)

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...